NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis $4.51 +0.16 (+3.68%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$4.56 +0.04 (+1.00%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Artelo Biosciences Stock (NASDAQ:ARTL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Artelo Biosciences alerts:Sign Up Key Stats Today's Range$4.30▼$4.7050-Day Range$4.35▼$28.5052-Week Range$4.20▼$28.60Volume234,531 shsAverage Volume77,263 shsMarket Capitalization$3.16 millionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingStrong Buy Company Overview Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Read More Artelo Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreARTL MarketRank™: Artelo Biosciences scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingStrong Buy Consensus RatingArtelo Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.60, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialArtelo Biosciences has a consensus price target of $24.00, representing about 432.2% upside from its current price of $4.51.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Artelo Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Artelo Biosciences are expected to grow in the coming year, from ($2.62) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtelo Biosciences has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Artelo Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.41% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently increased by 75.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.41% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently increased by 75.56%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.36 News SentimentArtelo Biosciences has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Artelo Biosciences this week, compared to 1 article on an average week.Search Interest5 people have searched for ARTL on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows5 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.80% of the stock of Artelo Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.87% of the stock of Artelo Biosciences is held by institutions.Read more about Artelo Biosciences' insider trading history. Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTL Stock News HeadlinesArtelo Biosciences, Inc. (NASDAQ:ARTL) Receives $24.00 Average Price Target from AnalystsSeptember 6 at 2:33 AM | americanbankingnews.comArtelo Biosciences Closes $3 Million Public Offering of Common Stock and Pre-Funded WarrantsSeptember 5 at 4:50 PM | quiverquant.comQTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.September 6 at 2:00 AM | Porter & Company (Ad)Artelo Biosciences Announces Closing of $3.0 Million Public OfferingSeptember 5 at 4:05 PM | globenewswire.comArtelo prices 640,924 shares at $4.40 in underwritten public offeringSeptember 4 at 3:45 PM | msn.comArtelo Biosciences Announces Pricing of $3.0 Million Public OfferingSeptember 4 at 8:37 AM | globenewswire.comArtelo Biosciences Announces Proposed Underwritten Public OfferingSeptember 3 at 4:35 PM | globenewswire.comArtelo does not envision need to internally fund Phase 3 trial of ART27.13September 3 at 4:07 PM | msn.comSee More Headlines ARTL Stock Analysis - Frequently Asked Questions How have ARTL shares performed this year? Artelo Biosciences' stock was trading at $6.36 at the beginning of the year. Since then, ARTL shares have decreased by 29.1% and is now trading at $4.51. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) issued its quarterly earnings results on Wednesday, August, 13th. The company reported ($5.61) EPS for the quarter, missing the consensus estimate of ($0.13) by $5.48. When did Artelo Biosciences' stock split? Artelo Biosciences's stock reverse split on Friday, June 13th 2025.The 1-6 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Artelo Biosciences' major shareholders? Artelo Biosciences' top institutional investors include Geode Capital Management LLC (2.29%). View institutional ownership trends. How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/13/2025Today9/06/2025Next Earnings (Estimated)11/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARTL CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Artelo Biosciences$24.00 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+432.2%Consensus RatingStrong Buy Rating Score (0-4)3.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($19.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-497.68% Return on Assets-213.76% Debt Debt-to-Equity RatioN/A Current Ratio0.39 Quick Ratio0.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book0.85Miscellaneous Outstanding Shares700,000Free Float663,000Market Cap$3.16 million OptionableNot Optionable Beta1.46 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ARTL) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.